Molecular Templates Price to Free Cash Flow Ratio 2010-2024 | MTEM

Molecular Templates price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as

Molecular Templates Price to Free Cash Flow Ratio 2010-2024 | MTEM

Molecular Templates price to free cash flow ratio from 2010 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$77.1B
Chugai Pharmaceutical (CHGCY)$71.1B
Takeda Pharmaceutical (TAK)$42.6B
Sandoz Group AG (SDZNY)$21B
Merck (MKKGY)$19.6B
Astellas Pharma (ALPMY)$17.5B
Summit Therapeutics (SMMT)$15.9B
United Therapeutics (UTHR)$15.7B
Neurocrine Biosciences (NBIX)$15.4B
Shionogi (SGIOY)$13B
Orion OYJ (ORINY)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.3B
Corcept Therapeutics (CORT)$7B
Stevanato Group S.p.A (STVN)$6.8B
Hikma Pharmaceuticals Plc (HKMPF)$5.9B
Ionis Pharmaceuticals (IONS)$5B
Grifols, S.A (GRFS)$4.7B
Ono Pharmaceutical (OPHLF)$4.3B
Crinetics Pharmaceuticals (CRNX)$3.7B
Recursion Pharmaceuticals (RXRX)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.6B
Centessa Pharmaceuticals (CNTA)$2.2B
Soleno Therapeutics (SLNO)$2.2B
NewAmsterdam Pharma (NAMS)$2.1B
Hypermarcas (HYPMY)$2B
Indivior (INDV)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
Evotec AG (EVO)$1.6B
Dyne Therapeutics (DYN)$1.4B